Multiply Labs, a cutting-edge robotics company specializing in automated manufacturing systems for personalized drugs, has entered into a non-exclusive partnership with Akron Bio, a leading supplier of essential materials and services for advanced therapies. The collaboration focuses on the automation and standardization of cytokine usage in cell therapy manufacturing.
By harnessing the capabilities of Multiply Labs' cell therapy robotic cluster, this partnership aims to automate Akron's cytokines, starting with cGMP-compliant rHu Interleukin-2 (IL-2). The integration of Akron's liquid IL-2 into Multiply Labs' cell therapy manufacturing workflow will be executed with precision, adhering to aseptic conditions and accurately formulating and dispensing the required amounts for diverse processes.
Akron and Multiply Labs will work together to integrate Akron's existing cGMP-compliant cytokines with Multiply Labs' proprietary adapter system. This integration ensures compatibility with Multiply Labs' cell therapy robotic clusters, allowing manufacturers currently using Akron's products to seamlessly incorporate these automated syringes into their existing equipment without significant alterations to their overall cell therapy manufacturing processes.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!